Impact of Clinical Pharmacist on the Quality and Cost of the Therapeutic Management of Patients in Two Medical Services of a Teaching Hospital (ImpactPharma)

June 17, 2026 updated by: Centre Hospitalier Universitaire de Nīmes

Incomplete information or poorly communicated to the transitional stages of the patient's drug therapy hospitalized cause medication errors. These steps are the admission, transfer within the institution and hospital discharge to home or another institution.

The adequacy of the prescription recommendations of good practice is not always optimal.

The cost of taking drug therapy and iatrogenic risks preventable drug-related weighs more and more heavily in health spending and in the prolongation of hospitalization or re hospitalization.

Clinical pharmacy widely practiced in the Anglo-Saxon countries has demonstrated its effectiveness on these three themes; it seems appropriate to assess this practice in the environment of the French health system.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Gard
      • Nîmes, Gard, France, 30029
        • CHU de Nîmes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • patients admitted in in infectious and tropical diseases unit or the internal medicine unit

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: BMO
Other: Pharmacist consultation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of prescriptions
Time Frame: 11 weeks
11 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Nīmes

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

August 24, 2016

First Submitted That Met QC Criteria

August 29, 2016

First Posted (Estimated)

September 1, 2016

Study Record Updates

Last Update Posted (Actual)

June 22, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • LOCAL/2010/JMK-01
  • 2010-A00186-35 (Other Identifier: ANSM)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe